<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03832621</url>
  </required_header>
  <id_info>
    <org_study_id>INT202-18</org_study_id>
    <nct_id>NCT03832621</nct_id>
  </id_info>
  <brief_title>NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer</brief_title>
  <acronym>MAYA</acronym>
  <official_title>NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and&#xD;
      safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27&#xD;
      patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in&#xD;
      treatment with single-agent TMZ.&#xD;
&#xD;
      Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset&#xD;
      of patients. A high number of tumor mutations (so called 'tumor mutational burden') has&#xD;
      recently been found associated with increased immunogenicity (due to a high number of&#xD;
      neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,&#xD;
      only a small fraction of tumors (&lt;5%) display a high mutational load and are usually&#xD;
      associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint&#xD;
      inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)&#xD;
      tumors, a hypothesis which was tested in various Phase II trials with positive results. On&#xD;
      the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune&#xD;
      checkpoint inhibitors.&#xD;
&#xD;
      Previous reports indicate that acquired resistance to TMZ may emerge through the induction of&#xD;
      a microsatellite-instability-positive phenotype and recent data showed that inactivation of&#xD;
      MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational&#xD;
      load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered&#xD;
      immune surveillance in mouse models.&#xD;
&#xD;
      On all of the above grounds, the investigators hypothesize that treatment of microsatellite&#xD;
      stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic&#xD;
      landscape by increasing the tumor mutational burden, leading to achieve potential&#xD;
      sensitization to immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In advanced CRC, the occurrence of chemorefractory disease poses a major therapeutic&#xD;
      challenge for presence of an adequate performance status to potentially receive further&#xD;
      treatments. Patients who progress after all approved treatments may be generally considered&#xD;
      suitable for new investigational drugs or strategies. Thus, in the era of personalized&#xD;
      medicine, tumor molecular profiling may lead to the identification of therapeutic targets or&#xD;
      predictive biomarkers for pharmacological intervention. The DNA repair gene&#xD;
      O6-methylguanine-DNA methyltransferase (MGMT) is responsible of the elimination of alkyl&#xD;
      groups from the O6-position of guanine. If inactive, it may be involved in early steps of&#xD;
      colorectal tumor genesis leading to an increase of G-to-A point mutations. Epigenetic&#xD;
      silencing of MGMT during colorectal tumor genesis is associated with hypermethylation of the&#xD;
      CpG island in its promoter. This transcriptional gene silencing is responsible for diminished&#xD;
      DNA-repair of O6-alkylguanine adducts, with the consequence of enhancing chemosensitivity to&#xD;
      alkylating agents including dacarbazine and its oral prodrug temozolomide (TMZ). Previous&#xD;
      phase II studies showed that TMZ induced an average objective response rate by RECIST&#xD;
      criteria in 10% of heavily pre-treated patients with advanced CRC carrying MGMT promoter&#xD;
      methylated tumors. Thus, MGMT methylation by methylation-specific PCR (MSP) used for patients&#xD;
      screening seemed to be a necessary but not sufficient condition to identify response to TMZ.&#xD;
      Digital PCR quantification of MGMT methylation refined patients' selection, with benefit&#xD;
      restricted to those with highly hyper-methylated tumors. Further analysis showed that MGMT&#xD;
      negative/low expression by immunohistochemistry (IHC) is found in about one third of&#xD;
      MSP-methylated samples and is associated with increased response rate. However, even in&#xD;
      responding mCRC patients, acquired resistance to single agent TMZ emerges rapidly and almost&#xD;
      invariably within 6 months from treatment initiation.&#xD;
&#xD;
      Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset&#xD;
      of patients. A high number of tumor mutations (so called 'tumor mutational burden') has&#xD;
      recently been found associated with increased immunogenicity (due to a high number of&#xD;
      neoantigens) and improved treatment efficacy across several different solid tumors. Early&#xD;
      clinical testing indicated that only 1 of 33 CRC patients had a response to anti PD-1&#xD;
      treatment, in contrast to substantial fractions of patients with melanomas, renal-cell&#xD;
      cancers, and lung tumors who showed benefit from PD-1 blockade. Similarly, anti CTLA-4&#xD;
      treatment up today brought to unsatisfactory results in unselected mCRC patients. The&#xD;
      probability of response has been ascribed to a high mutational burden (that is an elevated&#xD;
      number of somatic mutations), which translates in increased number of neo-antigens. In mCRCs,&#xD;
      only a small fraction of tumors (&lt;5%) display a high mutational load and are usually&#xD;
      associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Molecular&#xD;
      alterations in these genes occur as an initial step in colon tumor genesis leading to the&#xD;
      microsatellite instability (MSI) phenotype. Indeed, mismatch repair-deficient (dMMR)&#xD;
      colorectal cancers have 10 to 100 times as many somatic mutations as mismatch&#xD;
      repair-proficient colorectal cancers. Moreover, mismatch repair-deficient cancers contain&#xD;
      prominent lymphocyte infiltrates, a finding consistent with an immune response. Thus,&#xD;
      checkpoint inhibitors may have increased activity in dMMR/microsatellite instability-high&#xD;
      (MSI-H) tumors, a hypothesis which was tested in various Phase II trials with positive&#xD;
      results. On the opposite, mismatch repair proficient colorectal cancer is unresponsive to&#xD;
      immune checkpoint inhibitors.&#xD;
&#xD;
      Previous reports indicate that acquired resistance to TMZ may emerge through the induction of&#xD;
      a microsatellite-instability-positive phenotype. On the other hand, TMZ by itself has been&#xD;
      shown to induce an increase of mutational load in other MGMT deficient solid tumors such as&#xD;
      melanoma or glioblastoma. In parallel, other studies have demonstrated that alkylating&#xD;
      agents' side effects can influence the immune cell compartment by selectively depleting the&#xD;
      immuno-suppressive T regulator lymphocytes (Tregs), and activating the immuno-active T&#xD;
      cytotoxic lymphocytes (Tc) and natural killers (NK). The investigators recently showed that&#xD;
      inactivation of MMR, driven by acquired resistance to the clinical agent temozolomide,&#xD;
      increased mutational load, promoted continuous renewal of neoantigens in human colorectal&#xD;
      cancers and triggered immune surveillance in mouse models.&#xD;
&#xD;
      On all of the above grounds, the investigators hypothesize that treatment of microsatellite&#xD;
      stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic&#xD;
      landscape by increasing the tumor mutational burden either directly (by inducing G&gt;A&#xD;
      mutations) or/and indirectly (by inactivating DNA repair genes such as MLH1, MSH2 or MSH6,&#xD;
      which in turn could lead to hypermutated phenotype) therefore enhancing formation of cancer&#xD;
      neoantigens and immunogenicity. TMZ treatment can also modulate the repertoire of immune&#xD;
      cells (Tregs, Tc, NK) favoring T cell activation. To achieve potential sensitization to&#xD;
      immunotherapy by means of TMZ-induced MSI-like status, treatment with TMZ should be active&#xD;
      (i.e. inducing a SD/PR/CR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ</measure>
    <time_frame>8 months from the last patient enrolled</time_frame>
    <description>The primary efficacy endpoint of this study is 8-month PFS rate, defined as the proportion of patients alive and progression-free at 8 months from the enrollment.&#xD;
Investigator-assessed PFS according to RECIST v1.1 Investigator-assessed PFS according to modified RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the overall response rates (ORR) of the combination regimen of temozolomide, nivolumab and ipilimumab</measure>
    <time_frame>36 months</time_frame>
    <description>ORR measured by response rate according to RECIST 1.1 and modified RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate duration of response (DoR) of the combination regimen of temozolomide, nivolumab and ipilimumab</measure>
    <time_frame>36 months</time_frame>
    <description>DoR assessed per RECIST 1.1 and modified RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate overall survival (OS) of the combination regimen of temozolomide, nivolumab and ipilimumab</measure>
    <time_frame>36 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate ORR according to an Imaging Independent Central Review, using RECIST 1.1 and modified RECIST criteria</measure>
    <time_frame>36 moths</time_frame>
    <description>CD-ROM copies of the CT scans performed at baseline and during treatment until disease progression according to RECIST 1.1 and modified RECIST criteria will be collected at the Coordinating Center (S.C. Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori) for central review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the adverse events encountered by patients treated with the combination of temozolomide, nivolumab and ipilimumab</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with treatment-related adverse events graded according to the NCI CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate DoR of the combination regimen of temozolomide, nivolumab and ipilimumab according to an Imaging Independent Central Review</measure>
    <time_frame>36 months</time_frame>
    <description>DoR calculated after the Imaging Independent Central Review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate PFS of the combination regimen of temozolomide, nivolumab and ipilimumab according to an Imaging Independent Central Review</measure>
    <time_frame>36 months</time_frame>
    <description>PFS calculated after the Imaging Independent Central Review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess quality of life</measure>
    <time_frame>36 months</time_frame>
    <description>Quality of life will be assessed through Patient reported outcomes (PRO) instrument. PRO will be assessed by EORTC QLQ-C30 EORTC QLQ-CR29 and EuroQol EQ-5D</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate the relationship between tumor and plasma MGMT methylation</measure>
    <time_frame>36 months</time_frame>
    <description>Quantification of the percentage of MGMT methylation with digital PCR for MGMT methylation status will be performed in archival tumor tissue, tumor re-biopsies and cell-free circulating DNA (cfDNA) (cfDNA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the tumor mutational load</measure>
    <time_frame>36 months</time_frame>
    <description>Mutational load will be assessed in archival tumor tissues, tumor biopsies and cfDNA by means of whole exome sequencing</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>temozolomide + nivolumab + ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks</description>
    <arm_group_label>temozolomide + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>nivolumab 480 mg i.v. every 4 weeks</description>
    <arm_group_label>temozolomide + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks</description>
    <arm_group_label>temozolomide + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have provided written informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Willing and able to comply with the protocol&#xD;
&#xD;
          3. ≥18 years of age&#xD;
&#xD;
          4. ECOG status 0 - 1&#xD;
&#xD;
          5. At least 12 weeks of life expectancy at time of entry into the study&#xD;
&#xD;
          6. Histologically confirmed metastatic or inoperable adenocarcinoma of the colon and/or&#xD;
             rectum, with centrally confirmed mismatch repair proficiency (microsatellite stable&#xD;
             [MSS]) by multiplex polymerase chain reaction (PCR), MGMT promoter methylation by&#xD;
             methylation-specific PCR (MSP) and MGMT low expression by IHC&#xD;
&#xD;
          7. Patients with progressive disease or that are not candidate for oxaliplatin irinotecan&#xD;
             fluoropirimidin based chemotherapy and anti EGFR mAbs (in RAS/BRAF wild type tumors)&#xD;
             in the metastatic setting&#xD;
&#xD;
          8. Patients with documented disease relapsed within 6 months from the completion of&#xD;
             adjuvant oxaliplatin-based chemotherapy are considered eligible&#xD;
&#xD;
          9. Measureable, unresectable disease according to RECIST 1.1. Subjects with lesions in a&#xD;
             previously irradiated field as the sole site of measurable disease will be permitted&#xD;
             to enroll provided the lesion(s) have demonstrated clear progression and can be&#xD;
             measured accurately.&#xD;
&#xD;
         10. Is willing and able to provide an adequate archival tumor sample (FFPE) available for&#xD;
             tissue screening for central tissue screening. If the tumour block is not available, a&#xD;
             minimum of twenty 3-micron unstained sections on charged slides of tumor will be&#xD;
             required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Requirement for treatment with any medicinal product that contraindicates the use of&#xD;
             any of the study medications, may interfere with the planned treatment, affects&#xD;
             patient compliance or puts the patient at high risk for treatment-related&#xD;
             complications&#xD;
&#xD;
          2. Inability to swallow pills&#xD;
&#xD;
          3. Refractory nausea and vomiting, malabsorption, external biliary shunt or significant&#xD;
             bowel resection that would preclude adequate absorption&#xD;
&#xD;
          4. Inadequate haematological function indicated by all of the following:&#xD;
&#xD;
               -  White Blood Cell (WBC) count &lt; 2 x 109/L&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count &lt; 100 x 109/L&#xD;
&#xD;
               -  Haemoglobin &lt; 9 g/dL (patients may have transfusions and/or growth factors to&#xD;
                  attain adequate Hb)&#xD;
&#xD;
          5. Inadequate liver function indicated by all of the following:&#xD;
&#xD;
               -  Total bilirubin ≥ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≥ 3 x ULN (≥ 5 x&#xD;
                  ULN in patients with known liver metastases)&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≥ 2 x ULN (≥ 5 x ULN in patients with known liver&#xD;
                  metastases)&#xD;
&#xD;
          6. Inadequate renal function indicated by all of the following:&#xD;
&#xD;
             - Serum creatinine &gt; 1.5 x ULN or calculated creatinine clearance &lt; 40 ml/min&#xD;
&#xD;
          7. INR &gt; 1.5 and aPTT &gt; 1.5 x ULN within 7 days prior to the start of study treatment for&#xD;
             patients not receiving anti-coagulation&#xD;
&#xD;
             a. NOTE: The use of full-dose oral or parenteral anticoagulants is permitted as long&#xD;
             as the INR or aPTT is within therapeutic limits (according to the medical standard of&#xD;
             the enrolling institution) and the patient has been on a stable dose of anticoagulants&#xD;
             for at least two weeks prior to the start of study treatment&#xD;
&#xD;
          8. Active infection requiring intravenous antibiotics at the start of study treatment&#xD;
&#xD;
          9. Previous or concurrent malignancy, except for adequately treated basal or squamous&#xD;
             cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate,&#xD;
             cervix, or breast, or other cancer for which the patient has been disease-free for&#xD;
             three years prior to study entry&#xD;
&#xD;
         10. Evidence of any other disease, neurologic or metabolic dysfunction, physical&#xD;
             examination finding or laboratory finding giving reasonable suspicion of a disease or&#xD;
             condition that contraindicates the use of any of the study medications, puts the&#xD;
             patient at higher risk for treatment-related complications or may affect the&#xD;
             interpretation of study results&#xD;
&#xD;
         11. Clinically significant (i.e. active) cardiovascular disease, for example&#xD;
             cerebrovascular accidents ≤ 6 months prior to start of study treatment, myocardial&#xD;
             infarction ≤ 6 months prior to study enrolment, unstable angina, New York Heart&#xD;
             Association (NYHA) Functional Classification Grade II or greater congestive heart&#xD;
             failure, or serious cardiac arrhythmia uncontrolled by medication or potentially&#xD;
             interfering with protocol treatment&#xD;
&#xD;
         12. History or evidence upon physical or neurological examination of central nervous&#xD;
             system (CNS) disease (e.g. seizures) unrelated to cancer unless adequately treated&#xD;
             with standard medical therapy&#xD;
&#xD;
         13. Active brain metastases or leptomeningeal metastases. Subjects with brain metastases&#xD;
             are eligible if these have been treated and there is no magnetic resonance imaging&#xD;
             (MRI except where contraindicated in which CT scan is acceptable) evidence of&#xD;
             progression for at least 8 weeks after treatment is complete and within 28 days prior&#xD;
             to first dose of study drug administration. Cases should be discussed with the medical&#xD;
             monitor. There must also be no requirement for immunosuppressive doses of systemic&#xD;
             corticosteroids (&gt;10mg/day prednisone equivalents) for at least 2 weeks prior to study&#xD;
             drug administration.&#xD;
&#xD;
         14. Surgical procedure (including open biopsy, surgical resection, wound revision, or any&#xD;
             other major surgery involving entry into a body cavity) or significant traumatic&#xD;
             injury within 28 days prior to start of study treatment, or anticipation of need for&#xD;
             major surgical procedure during the course of the study.&#xD;
&#xD;
         15. Treatment with any chemotherapy, curative intent radiation therapy, biologics for&#xD;
             cancer, or investigational therapy within 28 days of first administration of study&#xD;
             treatment (subjects with prior cytotoxic or investigational products &lt; 4 weeks prior&#xD;
             to treatment might be eligible after discussion between investigator and sponsor, if&#xD;
             toxicities from the prior treatment have been resolved to Grade 1 (NCI CTCAE version&#xD;
             4). Prior focal palliative radiotherapy must have been completed at least 2 weeks&#xD;
             before study drug administration.&#xD;
&#xD;
         16. All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue&#xD;
             must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration&#xD;
             of study drug. Subjects with toxicities attributed to prior anti-cancer therapy which&#xD;
             are not expected to resolve and result in long lasting sequelae, such as neuropathy&#xD;
             after platinum based therapy, are permitted to enroll.&#xD;
&#xD;
         17. Known hypersensitivity to any of the study medications or Known hypersensitivity or&#xD;
             allergy to Chinese hamster ovary cell products or any component of the NIVO&#xD;
             formulation&#xD;
&#xD;
         18. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
         19. History of autoimmune disease including but not limited to myasthenia gravis,&#xD;
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid&#xD;
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,&#xD;
             multiple sclerosis, vasculitis, or glomerulonephritis (see Appendix IV for a more&#xD;
             comprehensive list of autoimmune diseases)&#xD;
&#xD;
             a. Note: history of autoimmune-related hypothyroidism on a stable dose of thyroid&#xD;
             replacement hormone may be eligible. Subjects with controlled type I diabetes mellitus&#xD;
             on a stable insulin regimen, vitiligo or psoriasis not requiring systemic treatment&#xD;
             may be eligible.&#xD;
&#xD;
         20. Prior allogeneic bone marrow transplantation or prior solid organ transplantation&#xD;
&#xD;
         21. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced&#xD;
             pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic&#xD;
             organizing pneumonia), or evidence of active pneumonitis on Screening chest CT scan&#xD;
&#xD;
         22. Treatment with systemic immunostimulatory agents (including but not limited to&#xD;
             interferons or interleukin-2) within 4 weeks or five half-lives of the drug, whichever&#xD;
             is shorter, prior to start of study treatment&#xD;
&#xD;
         23. Treatment with systemic corticosteroids (&gt;10 mg daily prednisone equivalents) or other&#xD;
             systemic immunosuppressive medications (including but not limited to prednisone,&#xD;
             dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
             anti-tumour necrosis factor [TNF] agents) within 2 weeks prior to start of study&#xD;
             treatment, or requirement for systemic immunosuppressive medications during the trial.&#xD;
             The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is&#xD;
             allowed.&#xD;
&#xD;
             a. Note: Patients who have received acute, low-dose, systemic immunosuppressant&#xD;
             medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the&#xD;
             study after discussion with and approval by the Sponsor.&#xD;
&#xD;
         24. Positive test for human immunodeficiency virus (HIV)&#xD;
&#xD;
         25. Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg]&#xD;
             test prior to randomization) or hepatitis C&#xD;
&#xD;
               1. Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV&#xD;
                  infection (defined as having a negative HBsAg test and a positive antibody to&#xD;
                  hepatitis B core antigen antibody test) are eligible. Patients with detectable&#xD;
                  HBV-DNA are not eligible.&#xD;
&#xD;
               2. Note: Patients positive for hepatitis C virus (HCV) antibody are eligible only if&#xD;
                  polymerase chain reaction testing is negative for HCV ribonucleic acid (RNA).&#xD;
&#xD;
         26. Active tuberculosis&#xD;
&#xD;
         27. Administration of a live, attenuated vaccine within 4 weeks prior to start of study&#xD;
             treatment or anticipation that such a live attenuated vaccine will be required during&#xD;
             the study&#xD;
&#xD;
         28. Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint&#xD;
             pathways, including prior therapy with anti-tumor vaccines.&#xD;
&#xD;
         29. Pregnancy or lactation. A serum pregnancy test is required within 7 days prior to&#xD;
             start of study treatment, or within 14 days with a confirmatory urine pregnancy test&#xD;
             within 7 days prior start of study treatment&#xD;
&#xD;
         30. For women who are not post-menopausal (&lt; 12 months of non-therapy-induced amenorrhea)&#xD;
             or surgically sterile (absence of ovaries and/or uterus): refusal to use a highly&#xD;
             effective contraceptive method (i.e. with a failure rate of &lt; 1% per year such as&#xD;
             sexual abstinence, hormonal implants, combined oral contraceptives, vasectomised&#xD;
             partner), during the study drug administration and for at least 6 months after the&#xD;
             last dose of study medication. Periodic abstinence [e.g., calendar, ovulation,&#xD;
             symptothermal, postovulation methods] and withdrawal are not acceptable methods of&#xD;
             contraception. A combination of male condom with cap, diaphragm or sponge with&#xD;
             spermicide (double barrier methods) is not considered highly effective, birth control&#xD;
             methods. Acceptable methods of contraception may include total abstinence in cases&#xD;
             where the lifestyle of the patient ensures compliance. A Vasectomised partner is a&#xD;
             highly effective birth control method provided that partner is the sole sexual partner&#xD;
             of the trial participant and that the vasectomised partner has received medical&#xD;
             assessment of the surgical success.&#xD;
&#xD;
         31. For men: refusal to use a highly effective contraceptive method (i.e. with a failure&#xD;
             rate of &lt; 1 % per year such as vasectomy, sexual abstinence or female partner use of&#xD;
             hormonal implants or combined oral contraceptives) during the study drug&#xD;
             administration and for a period of at least 6 months after the last dose of study&#xD;
             medication. Periodic abstinence [e.g., calendar, ovulation, symptothermal, post&#xD;
             ovulation methods] and withdrawal are not acceptable methods of contraception. A&#xD;
             combination of male condom with either, cap, diaphragm or sponge with spermicide&#xD;
             (double barrier methods) is not considered highly effective, birth control methods.&#xD;
             Acceptable methods of contraception may include total abstinence in cases where the&#xD;
             lifestyle of the patient ensures compliance. A vasectomised trial participant is a&#xD;
             highly effective birth control method provided that the trial participant has received&#xD;
             medical assessment of the surgical success.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Pietrantonio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012 Oct;23(10):2479-2516. doi: 10.1093/annonc/mds236.</citation>
    <PMID>23012255</PMID>
  </reference>
  <reference>
    <citation>Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: where to fit the target. World J Gastroenterol. 2014 Feb 28;20(8):1993-2004. doi: 10.3748/wjg.v20.i8.1993.</citation>
    <PMID>24616571</PMID>
  </reference>
  <reference>
    <citation>Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol. 2014 Jan 28;20(4):899-907. doi: 10.3748/wjg.v20.i4.899.</citation>
    <PMID>24574764</PMID>
  </reference>
  <reference>
    <citation>Tejpar S, Piessevaux H. Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity? Asia Pac J Clin Oncol. 2014 Mar;10 Suppl 1:2-10. doi: 10.1111/ajco.12176.</citation>
    <PMID>24512508</PMID>
  </reference>
  <reference>
    <citation>Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Crit Rev Oncol Hematol. 2014 Jul;91(1):9-34. doi: 10.1016/j.critrevonc.2014.01.001. Epub 2014 Jan 15.</citation>
    <PMID>24534706</PMID>
  </reference>
  <reference>
    <citation>Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.</citation>
    <PMID>23177514</PMID>
  </reference>
  <reference>
    <citation>Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.</citation>
    <PMID>25970050</PMID>
  </reference>
  <reference>
    <citation>Oberg A, Samii S, Stenling R, Lindmark G. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis. 2002 Jan;17(1):25-9. doi: 10.1007/s003840100337.</citation>
    <PMID>12018450</PMID>
  </reference>
  <reference>
    <citation>Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960-4. doi: 10.1126/science.1129139.</citation>
    <PMID>17008531</PMID>
  </reference>
  <reference>
    <citation>Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009 Dec 10;27(35):5944-51. doi: 10.1200/JCO.2008.19.6147. Epub 2009 Oct 26.</citation>
    <PMID>19858404</PMID>
  </reference>
  <reference>
    <citation>Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum In: N Engl J Med. 2010 Sep 23;363(13):1290.</citation>
    <PMID>20525992</PMID>
  </reference>
  <reference>
    <citation>Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.</citation>
    <PMID>26115796</PMID>
  </reference>
  <reference>
    <citation>Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.</citation>
    <PMID>26028407</PMID>
  </reference>
  <reference>
    <citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.</citation>
    <PMID>22658127</PMID>
  </reference>
  <reference>
    <citation>Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013 Jan 15;19(2):462-8. doi: 10.1158/1078-0432.CCR-12-2625. Epub 2012 Nov 20.</citation>
    <PMID>23169436</PMID>
  </reference>
  <reference>
    <citation>Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.</citation>
    <PMID>26028255</PMID>
  </reference>
  <reference>
    <citation>Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.</citation>
    <PMID>22658128</PMID>
  </reference>
  <reference>
    <citation>Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May;25(5):1032-8. doi: 10.1093/annonc/mdu100. Epub 2014 Feb 27.</citation>
    <PMID>24585723</PMID>
  </reference>
  <reference>
    <citation>Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Krieken JH. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009 Jan 27;100(2):266-73. doi: 10.1038/sj.bjc.6604867.</citation>
    <PMID>19165197</PMID>
  </reference>
  <reference>
    <citation>Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008 Feb 1;68(3):889-92. doi: 10.1158/0008-5472.CAN-07-3095.</citation>
    <PMID>18245491</PMID>
  </reference>
  <reference>
    <citation>Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul 18;487(7407):330-7. doi: 10.1038/nature11252.</citation>
    <PMID>22810696</PMID>
  </reference>
  <reference>
    <citation>Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One. 2010 Dec 22;5(12):e15661. doi: 10.1371/journal.pone.0015661.</citation>
    <PMID>21203531</PMID>
  </reference>
  <reference>
    <citation>Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001 Jun 15;91(12):2417-22.</citation>
    <PMID>11413533</PMID>
  </reference>
  <reference>
    <citation>Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum In: Lancet Oncol. 2017 Sep;18(9):e510.</citation>
    <PMID>28734759</PMID>
  </reference>
  <reference>
    <citation>Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.</citation>
    <PMID>28596308</PMID>
  </reference>
  <reference>
    <citation>Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene. 2004 Jan 8;23(1):1-8. doi: 10.1038/sj.onc.1207316.</citation>
    <PMID>14712205</PMID>
  </reference>
  <reference>
    <citation>Ju HX, An B, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, Hirai T, Shimizu Y, Sano T, Sawaki A, Tajika M, Yamao K, Fujii M, Murakami H, Osada H, Ito H, Takeuchi I, Sekido Y, Kondo Y. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol. 2011 Apr;178(4):1835-46. doi: 10.1016/j.ajpath.2010.12.045. Epub 2011 Mar 4.</citation>
    <PMID>21406167</PMID>
  </reference>
  <reference>
    <citation>Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomata C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Ruda R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol. 2015 Sep;26(9):1994-1999. doi: 10.1093/annonc/mdv272. Epub 2015 Jun 25.</citation>
    <PMID>26113646</PMID>
  </reference>
  <reference>
    <citation>Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS, Ogino S. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control. 2011 Feb;22(2):301-9. doi: 10.1007/s10552-010-9698-z. Epub 2010 Dec 8.</citation>
    <PMID>21140203</PMID>
  </reference>
  <reference>
    <citation>Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013 Apr 15;19(8):2265-72. doi: 10.1158/1078-0432.CCR-12-3518. Epub 2013 Feb 19.</citation>
    <PMID>23422094</PMID>
  </reference>
  <reference>
    <citation>Hochhauser D, Glynne-Jones R, Potter V, Gravalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.</citation>
    <PMID>23443801</PMID>
  </reference>
  <reference>
    <citation>Pietrantonio F, Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol. 2014 Feb;25(2):404-8. doi: 10.1093/annonc/mdt547. Epub 2013 Dec 29.</citation>
    <PMID>24379162</PMID>
  </reference>
  <reference>
    <citation>Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, Vogelstein B, Lengauer C. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5770-5. doi: 10.1073/pnas.081082898. Epub 2001 Apr 10.</citation>
    <PMID>11296254</PMID>
  </reference>
  <reference>
    <citation>Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009 Jul 15;15(14):4622-9. doi: 10.1158/1078-0432.CCR-08-3012. Epub 2009 Jul 7. Erratum In: Clin Cancer Res. 2013 Aug 15;19(16):4543-4.</citation>
    <PMID>19584161</PMID>
  </reference>
  <reference>
    <citation>Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, Stratton MR. Clock-like mutational processes in human somatic cells. Nat Genet. 2015 Dec;47(12):1402-7. doi: 10.1038/ng.3441. Epub 2015 Nov 9.</citation>
    <PMID>26551669</PMID>
  </reference>
  <reference>
    <citation>Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004 Feb 15;22(4):610-6. doi: 10.1200/JCO.2004.07.060. Epub 2004 Jan 15. Erratum In: J Clin Oncol. 2004 May 15;22(10):2038.</citation>
    <PMID>14726505</PMID>
  </reference>
  <reference>
    <citation>Hervieu A, Rebe C, Vegran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013 Feb;133(2):499-508. doi: 10.1038/jid.2012.273. Epub 2012 Sep 6.</citation>
    <PMID>22951720</PMID>
  </reference>
  <reference>
    <citation>Fritzell S, Sanden E, Eberstal S, Visse E, Darabi A, Siesjo P. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. Cancer Immunol Immunother. 2013 Sep;62(9):1463-74. doi: 10.1007/s00262-013-1449-z. Epub 2013 Jun 18.</citation>
    <PMID>23775421</PMID>
  </reference>
  <reference>
    <citation>Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007 Mar;8(3):239-45. doi: 10.1038/ni1443.</citation>
    <PMID>17304234</PMID>
  </reference>
  <reference>
    <citation>Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.</citation>
    <PMID>21639810</PMID>
  </reference>
  <reference>
    <citation>Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. Target Oncol. 2016 Jun;11(3):337-43. doi: 10.1007/s11523-015-0397-2.</citation>
    <PMID>26538496</PMID>
  </reference>
  <reference>
    <citation>Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br J Cancer. 2017 May 9;116(10):1279-1286. doi: 10.1038/bjc.2017.109. Epub 2017 Apr 20.</citation>
    <PMID>28427088</PMID>
  </reference>
  <reference>
    <citation>Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011 Feb 15;71(4):1263-71. doi: 10.1158/0008-5472.CAN-10-2907. Epub 2011 Feb 8. Erratum In: Cancer Res. 2011 Jul 1;71(13):4732.</citation>
    <PMID>21303976</PMID>
  </reference>
  <reference>
    <citation>Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001 Jan;25(1):1-12. doi: 10.1016/s0145-2126(00)00093-x.</citation>
    <PMID>11137554</PMID>
  </reference>
  <reference>
    <citation>Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C, Gaidano G, Malavasi F, Deaglio S. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia. 2010 May;24(5):958-69. doi: 10.1038/leu.2010.36. Epub 2010 Mar 11.</citation>
    <PMID>20220774</PMID>
  </reference>
  <reference>
    <citation>Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011 Sep 29;118(13):3470-8. doi: 10.1182/blood-2011-06-275610. Epub 2011 Jul 15.</citation>
    <PMID>21765022</PMID>
  </reference>
  <reference>
    <citation>Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.</citation>
    <PMID>19934295</PMID>
  </reference>
  <reference>
    <citation>Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol. 2012 Dec;35(6):606-11. doi: 10.1097/COC.0b013e318209cda9.</citation>
    <PMID>21336089</PMID>
  </reference>
  <reference>
    <citation>Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015.</citation>
    <PMID>21074069</PMID>
  </reference>
  <reference>
    <citation>Marventano S, Forjaz M, Grosso G, Mistretta A, Giorgianni G, Platania A, Gangi S, Basile F, Biondi A. Health related quality of life in colorectal cancer patients: state of the art. BMC Surg. 2013;13 Suppl 2(Suppl 2):S15. doi: 10.1186/1471-2482-13-S2-S15. Epub 2013 Oct 8.</citation>
    <PMID>24267735</PMID>
  </reference>
  <reference>
    <citation>Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010 Oct;37(5):499-507. doi: 10.1053/j.seminoncol.2010.09.007.</citation>
    <PMID>21074065</PMID>
  </reference>
  <reference>
    <citation>Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000 May 1;60(9):2368-71.</citation>
    <PMID>10811111</PMID>
  </reference>
  <reference>
    <citation>Oesch F, Klein S. Relevance of environmental alkylating agents to repair protein O6-alkylguanine-DNA alkyltransferase: determination of individual and collective repair capacities of O6-methylguanine. Cancer Res. 1992 Apr 1;52(7):1801-3.</citation>
    <PMID>1532345</PMID>
  </reference>
  <reference>
    <citation>Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.</citation>
    <PMID>26970723</PMID>
  </reference>
  <reference>
    <citation>Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.</citation>
    <PMID>26952546</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>April 1, 2022</last_update_submitted>
  <last_update_submitted_qc>April 1, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nivolumab</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>temozolomide</keyword>
  <keyword>microsatellite stable</keyword>
  <keyword>MSS</keyword>
  <keyword>MGMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03832621
org study id: INT202-18
nct id: NCT03832621
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and
      safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27
      patients with MSS, MGMT-silenced mCRC with initial clinical benefit following lead-in
      treatment with single-agent TMZ.

      Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset
      of patients. A high number of tumor mutations (so called 'tumor mutational burden') has
      recently been found associated with increased immunogenicity (due to a high number of
      neoantigens) and improved treatment efficacy across several different solid tumors. In mCRCs,
      only a small fraction of tumors (<5%) display a high mutational load and are usually
      associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Checkpoint
      inhibitors may have increased activity in dMMR/microsatellite instability-high (MSI-H)
      tumors, a hypothesis which was tested in various Phase II trials with positive results. On
      the opposite, mismatch repair proficient colorectal cancer is unresponsive to immune
      checkpoint inhibitors.

      Previous reports indicate that acquired resistance to TMZ may emerge through the induction of
      a microsatellite-instability-positive phenotype and recent data showed that inactivation of
      MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational
      load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered
      immune surveillance in mouse models.

      On all of the above grounds, the investigators hypothesize that treatment of microsatellite
      stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic
      landscape by increasing the tumor mutational burden, leading to achieve potential
      sensitization to immunotherapy.
In advanced CRC, the occurrence of chemorefractory disease poses a major therapeutic
      challenge for presence of an adequate performance status to potentially receive further
      treatments. Patients who progress after all approved treatments may be generally considered
      suitable for new investigational drugs or strategies. Thus, in the era of personalized
      medicine, tumor molecular profiling may lead to the identification of therapeutic targets or
      predictive biomarkers for pharmacological intervention. The DNA repair gene
      O6-methylguanine-DNA methyltransferase (MGMT) is responsible of the elimination of alkyl
      groups from the O6-position of guanine. If inactive, it may be involved in early steps of
      colorectal tumor genesis leading to an increase of G-to-A point mutations. Epigenetic
      silencing of MGMT during colorectal tumor genesis is associated with hypermethylation of the
      CpG island in its promoter. This transcriptional gene silencing is responsible for diminished
      DNA-repair of O6-alkylguanine adducts, with the consequence of enhancing chemosensitivity to
      alkylating agents including dacarbazine and its oral prodrug temozolomide (TMZ). Previous
      phase II studies showed that TMZ induced an average objective response rate by RECIST
      criteria in 10% of heavily pre-treated patients with advanced CRC carrying MGMT promoter
      methylated tumors. Thus, MGMT methylation by methylation-specific PCR (MSP) used for patients
      screening seemed to be a necessary but not sufficient condition to identify response to TMZ.
      Digital PCR quantification of MGMT methylation refined patients' selection, with benefit
      restricted to those with highly hyper-methylated tumors. Further analysis showed that MGMT
      negative/low expression by immunohistochemistry (IHC) is found in about one third of
      MSP-methylated samples and is associated with increased response rate. However, even in
      responding mCRC patients, acquired resistance to single agent TMZ emerges rapidly and almost
      invariably within 6 months from treatment initiation.

      Immune checkpoint inhibitors have been shown to trigger durable antitumor effects in a subset
      of patients. A high number of tumor mutations (so called 'tumor mutational burden') has
      recently been found associated with increased immunogenicity (due to a high number of
      neoantigens) and improved treatment efficacy across several different solid tumors. Early
      clinical testing indicated that only 1 of 33 CRC patients had a response to anti PD-1
      treatment, in contrast to substantial fractions of patients with melanomas, renal-cell
      cancers, and lung tumors who showed benefit from PD-1 blockade. Similarly, anti CTLA-4
      treatment up today brought to unsatisfactory results in unselected mCRC patients. The
      probability of response has been ascribed to a high mutational burden (that is an elevated
      number of somatic mutations), which translates in increased number of neo-antigens. In mCRCs,
      only a small fraction of tumors (<5%) display a high mutational load and are usually
      associated with inactivation of mismatch repair genes such as MLH1, MSH2 and MSH6. Molecular
      alterations in these genes occur as an initial step in colon tumor genesis leading to the
      microsatellite instability (MSI) phenotype. Indeed, mismatch repair-deficient (dMMR)
      colorectal cancers have 10 to 100 times as many somatic mutations as mismatch
      repair-proficient colorectal cancers. Moreover, mismatch repair-deficient cancers contain
      prominent lymphocyte infiltrates, a finding consistent with an immune response. Thus,
      checkpoint inhibitors may have increased activity in dMMR/microsatellite instability-high
      (MSI-H) tumors, a hypothesis which was tested in various Phase II trials with positive
      results. On the opposite, mismatch repair proficient colorectal cancer is unresponsive to
      immune checkpoint inhibitors.

      Previous reports indicate that acquired resistance to TMZ may emerge through the induction of
      a microsatellite-instability-positive phenotype. On the other hand, TMZ by itself has been
      shown to induce an increase of mutational load in other MGMT deficient solid tumors such as
      melanoma or glioblastoma. In parallel, other studies have demonstrated that alkylating
      agents' side effects can influence the immune cell compartment by selectively depleting the
      immuno-suppressive T regulator lymphocytes (Tregs), and activating the immuno-active T
      cytotoxic lymphocytes (Tc) and natural killers (NK). The investigators recently showed that
      inactivation of MMR, driven by acquired resistance to the clinical agent temozolomide,
      increased mutational load, promoted continuous renewal of neoantigens in human colorectal
      cancers and triggered immune surveillance in mouse models.

      On all of the above grounds, the investigators hypothesize that treatment of microsatellite
      stable MGMT hypermethylated CRCs with alkylating agents could reshape the tumor genetic
      landscape by increasing the tumor mutational burden either directly (by inducing G>A
      mutations) or/and indirectly (by inactivating DNA repair genes such as MLH1, MSH2 or MSH6,
      which in turn could lead to hypermutated phenotype) therefore enhancing formation of cancer
      neoantigens and immunogenicity. TMZ treatment can also modulate the repertoire of immune
      cells (Tregs, Tc, NK) favoring T cell activation. To achieve potential sensitization to
      immunotherapy by means of TMZ-induced MSI-like status, treatment with TMZ should be active
      (i.e. inducing a SD/PR/CR).
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ
time frame: 8 months from the last patient enrolled
description: The primary efficacy endpoint of this study is 8-month PFS rate, defined as the proportion of patients alive and progression-free at 8 months from the enrollment.
Investigator-assessed PFS according to RECIST v1.1 Investigator-assessed PFS according to modified RECIST
measure: Estimate the overall response rates (ORR) of the combination regimen of temozolomide, nivolumab and ipilimumab
time frame: 36 months
description: ORR measured by response rate according to RECIST 1.1 and modified RECIST criteria
measure: Estimate duration of response (DoR) of the combination regimen of temozolomide, nivolumab and ipilimumab
time frame: 36 months
description: DoR assessed per RECIST 1.1 and modified RECIST
measure: Estimate overall survival (OS) of the combination regimen of temozolomide, nivolumab and ipilimumab
time frame: 36 months
description: overall survival
measure: Estimate ORR according to an Imaging Independent Central Review, using RECIST 1.1 and modified RECIST criteria
time frame: 36 moths
description: CD-ROM copies of the CT scans performed at baseline and during treatment until disease progression according to RECIST 1.1 and modified RECIST criteria will be collected at the Coordinating Center (S.C. Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori) for central review
measure: Evaluate the adverse events encountered by patients treated with the combination of temozolomide, nivolumab and ipilimumab
time frame: 36 months
description: Number of participants with treatment-related adverse events graded according to the NCI CTCAE v4.0
measure: Estimate DoR of the combination regimen of temozolomide, nivolumab and ipilimumab according to an Imaging Independent Central Review
time frame: 36 months
description: DoR calculated after the Imaging Independent Central Review
measure: Estimate PFS of the combination regimen of temozolomide, nivolumab and ipilimumab according to an Imaging Independent Central Review
time frame: 36 months
description: PFS calculated after the Imaging Independent Central Review
measure: Assess quality of life
time frame: 36 months
description: Quality of life will be assessed through Patient reported outcomes (PRO) instrument. PRO will be assessed by EORTC QLQ-C30 EORTC QLQ-CR29 and EuroQol EQ-5D
measure: Evaluate the relationship between tumor and plasma MGMT methylation
time frame: 36 months
description: Quantification of the percentage of MGMT methylation with digital PCR for MGMT methylation status will be performed in archival tumor tissue, tumor re-biopsies and cell-free circulating DNA (cfDNA) (cfDNA)
measure: Evaluate the tumor mutational load
time frame: 36 months
description: Mutational load will be assessed in archival tumor tissues, tumor biopsies and cfDNA by means of whole exome sequencing
arm group label: temozolomide + nivolumab + ipilimumab
arm group type: Experimental
description: Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule
intervention type: Drug
intervention name: Temozolomide
description: temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
arm group label: temozolomide + nivolumab + ipilimumab
intervention type: Drug
intervention name: Nivolumab
description: nivolumab 480 mg i.v. every 4 weeks
arm group label: temozolomide + nivolumab + ipilimumab
intervention type: Drug
intervention name: Ipilimumab
description: low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
arm group label: temozolomide + nivolumab + ipilimumab
criteria: 
gender: All
minimum age: 18 Years
maximum age: 99 Years
healthy volunteers: No
last name: Filippo Pietrantonio, MD
role: Principal Investigator
affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
facility: 
country: Italy
citation: Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012 Oct;23(10):2479-2516. doi: 10.1093/annonc/mds236.
PMID: 23012255
citation: Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: where to fit the target. World J Gastroenterol. 2014 Feb 28;20(8):1993-2004. doi: 10.3748/wjg.v20.i8.1993.
PMID: 24616571
citation: Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol. 2014 Jan 28;20(4):899-907. doi: 10.3748/wjg.v20.i4.899.
PMID: 24574764
citation: Tejpar S, Piessevaux H. Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity? Asia Pac J Clin Oncol. 2014 Mar;10 Suppl 1:2-10. doi: 10.1111/ajco.12176.
PMID: 24512508
citation: Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Crit Rev Oncol Hematol. 2014 Jul;91(1):9-34. doi: 10.1016/j.critrevonc.2014.01.001. Epub 2014 Jan 15.
PMID: 24534706
citation: Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
PMID: 23177514
citation: Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.
PMID: 25970050
citation: Oberg A, Samii S, Stenling R, Lindmark G. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis. 2002 Jan;17(1):25-9. doi: 10.1007/s003840100337.
PMID: 12018450
citation: Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960-4. doi: 10.1126/science.1129139.
PMID: 17008531
citation: Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009 Dec 10;27(35):5944-51. doi: 10.1200/JCO.2008.19.6147. Epub 2009 Oct 26.
PMID: 19858404
citation: Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum In: N Engl J Med. 2010 Sep 23;363(13):1290.
PMID: 20525992
citation: Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.
PMID: 26115796
citation: Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
PMID: 26028407
citation: Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
PMID: 22658127
citation: Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013 Jan 15;19(2):462-8. doi: 10.1158/1078-0432.CCR-12-2625. Epub 2012 Nov 20.
PMID: 23169436
citation: Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
PMID: 26028255
citation: Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
PMID: 22658128
citation: Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May;25(5):1032-8. doi: 10.1093/annonc/mdu100. Epub 2014 Feb 27.
PMID: 24585723
citation: Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Krieken JH. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009 Jan 27;100(2):266-73. doi: 10.1038/sj.bjc.6604867.
PMID: 19165197
citation: Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008 Feb 1;68(3):889-92. doi: 10.1158/0008-5472.CAN-07-3095.
PMID: 18245491
citation: Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul 18;487(7407):330-7. doi: 10.1038/nature11252.
PMID: 22810696
citation: Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One. 2010 Dec 22;5(12):e15661. doi: 10.1371/journal.pone.0015661.
PMID: 21203531
citation: Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001 Jun 15;91(12):2417-22.
PMID: 11413533
citation: Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum In: Lancet Oncol. 2017 Sep;18(9):e510.
PMID: 28734759
citation: Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
PMID: 28596308
citation: Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene. 2004 Jan 8;23(1):1-8. doi: 10.1038/sj.onc.1207316.
PMID: 14712205
citation: Ju HX, An B, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, Hirai T, Shimizu Y, Sano T, Sawaki A, Tajika M, Yamao K, Fujii M, Murakami H, Osada H, Ito H, Takeuchi I, Sekido Y, Kondo Y. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol. 2011 Apr;178(4):1835-46. doi: 10.1016/j.ajpath.2010.12.045. Epub 2011 Mar 4.
PMID: 21406167
citation: Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomata C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Ruda R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol. 2015 Sep;26(9):1994-1999. doi: 10.1093/annonc/mdv272. Epub 2015 Jun 25.
PMID: 26113646
citation: Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS, Ogino S. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control. 2011 Feb;22(2):301-9. doi: 10.1007/s10552-010-9698-z. Epub 2010 Dec 8.
PMID: 21140203
citation: Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013 Apr 15;19(8):2265-72. doi: 10.1158/1078-0432.CCR-12-3518. Epub 2013 Feb 19.
PMID: 23422094
citation: Hochhauser D, Glynne-Jones R, Potter V, Gravalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.
PMID: 23443801
citation: Pietrantonio F, Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol. 2014 Feb;25(2):404-8. doi: 10.1093/annonc/mdt547. Epub 2013 Dec 29.
PMID: 24379162
citation: Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, Vogelstein B, Lengauer C. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5770-5. doi: 10.1073/pnas.081082898. Epub 2001 Apr 10.
PMID: 11296254
citation: Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009 Jul 15;15(14):4622-9. doi: 10.1158/1078-0432.CCR-08-3012. Epub 2009 Jul 7. Erratum In: Clin Cancer Res. 2013 Aug 15;19(16):4543-4.
PMID: 19584161
citation: Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, Stratton MR. Clock-like mutational processes in human somatic cells. Nat Genet. 2015 Dec;47(12):1402-7. doi: 10.1038/ng.3441. Epub 2015 Nov 9.
PMID: 26551669
citation: Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004 Feb 15;22(4):610-6. doi: 10.1200/JCO.2004.07.060. Epub 2004 Jan 15. Erratum In: J Clin Oncol. 2004 May 15;22(10):2038.
PMID: 14726505
citation: Hervieu A, Rebe C, Vegran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013 Feb;133(2):499-508. doi: 10.1038/jid.2012.273. Epub 2012 Sep 6.
PMID: 22951720
citation: Fritzell S, Sanden E, Eberstal S, Visse E, Darabi A, Siesjo P. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. Cancer Immunol Immunother. 2013 Sep;62(9):1463-74. doi: 10.1007/s00262-013-1449-z. Epub 2013 Jun 18.
PMID: 23775421
citation: Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007 Mar;8(3):239-45. doi: 10.1038/ni1443.
PMID: 17304234
citation: Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.
PMID: 21639810
citation: Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. Target Oncol. 2016 Jun;11(3):337-43. doi: 10.1007/s11523-015-0397-2.
PMID: 26538496
citation: Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br J Cancer. 2017 May 9;116(10):1279-1286. doi: 10.1038/bjc.2017.109. Epub 2017 Apr 20.
PMID: 28427088
citation: Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011 Feb 15;71(4):1263-71. doi: 10.1158/0008-5472.CAN-10-2907. Epub 2011 Feb 8. Erratum In: Cancer Res. 2011 Jul 1;71(13):4732.
PMID: 21303976
citation: Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001 Jan;25(1):1-12. doi: 10.1016/s0145-2126(00)00093-x.
PMID: 11137554
citation: Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C, Gaidano G, Malavasi F, Deaglio S. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia. 2010 May;24(5):958-69. doi: 10.1038/leu.2010.36. Epub 2010 Mar 11.
PMID: 20220774
citation: Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011 Sep 29;118(13):3470-8. doi: 10.1182/blood-2011-06-275610. Epub 2011 Jul 15.
PMID: 21765022
citation: Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.
PMID: 19934295
citation: Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol. 2012 Dec;35(6):606-11. doi: 10.1097/COC.0b013e318209cda9.
PMID: 21336089
citation: Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015.
PMID: 21074069
citation: Marventano S, Forjaz M, Grosso G, Mistretta A, Giorgianni G, Platania A, Gangi S, Basile F, Biondi A. Health related quality of life in colorectal cancer patients: state of the art. BMC Surg. 2013;13 Suppl 2(Suppl 2):S15. doi: 10.1186/1471-2482-13-S2-S15. Epub 2013 Oct 8.
PMID: 24267735
citation: Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010 Oct;37(5):499-507. doi: 10.1053/j.seminoncol.2010.09.007.
PMID: 21074065
citation: Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000 May 1;60(9):2368-71.
PMID: 10811111
citation: Oesch F, Klein S. Relevance of environmental alkylating agents to repair protein O6-alkylguanine-DNA alkyltransferase: determination of individual and collective repair capacities of O6-methylguanine. Cancer Res. 1992 Apr 1;52(7):1801-3.
PMID: 1532345
citation: Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.
PMID: 26970723
citation: Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.
PMID: 26952546
responsible party type: Sponsor
mesh term: Colorectal Neoplasms
mesh term: Nivolumab
mesh term: Ipilimumab
mesh term: Temozolomide